Topical and Oral Anti-inflammatory Activity of Budesonide Compared with Oral Prednisolone in an Animal Model Using Allergen-induced Gut Mucosal Exudation of Plasma as a Marker

References

• Waldman TA. Gastrointestinal protein loss demonstrated by 51Cr-labelled albumin. Lancet 1961;2:121–3.
   PubMed Web of Science ®Google Scholar
• Beeken WL, Busch HJ, Sylwester DL. Intestinal protein loss in Crohn’s disease. Gastroenterology 1972;62:207–15.
   PubMed Web of Science ®Google Scholar
• Bernier JJ, Florent C, Desmazures C, Aymes C. Diagnosis of protein-losing enteropathy by gastrointestinal clearance of alpha1-antitrypsin. Lancet 1978;2:763–4.
   PubMed Web of Science ®Google Scholar
• O’Mahony S, Choudari CP, Barton JR, Walker S. Gut lavage fluid proteins as markers of activity of inflammatory bowel disease. Scand J Gastroenterol 1991;26:940–4.
   Google Scholar
• Choudari C, O’Mahony S, Brydon G, Mwantembe O. Gut lavage fluid protein concentrations: objective measures of disease activity in inflammatory bowel disease. Gastroenterology 1993;104:1064–71.
   PubMed Web of Science ®Google Scholar
• Persson CG, Erjefält JS, Greiff L, Erjefält I, Korsgren M, Linden M, et al. Contribution of plasma derived molecules to mucosal defence, disease, and repair. Scand J Immunol 1998;47:302–13.
   PubMed Web of Science ®Google Scholar
• Gustafsson B, Persson CGA. Allergen-induced mucosal exudation of plasma into the rat ileum and its inhibition by budesonide. Scand J Gastroenterol 1992;27:587–93.
   PubMed Web of Science ®Google Scholar
• Persson CGA, Gusafsson B, Eijefält JS, Sundler F. Mucosal exudation of plasma is a noninjurious intestinal defense mechanism. Allergy 1993;48:581–6.
   Google Scholar
• Miller-Larsson A, Gustafsson B, Brattsand R, Persson CGA. Mucosal uptake and retention of steroids in rat ileum. Possible explanation of topical efficacy in inflammatory bowel disease (IBD). Gastroenterology 1995;108 Suppl 4:A876.
   Google Scholar
• Ryrfeldt Å, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982;63 Suppl 122:86–95.
   Google Scholar
• Erjefält I, Greiff L, Alkner U, Persson CGA. Allergen-induced biphasic plasma exudation responses in guinea-pig large airways. Am Rev Respir Dis 1993;148:695–701.
   Google Scholar
• Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4:407–14.
   Google Scholar
• Thieson A, Thomson ABR. Older systemic and newer topical glucocorticosteroids and the gastrointestinal tract [Review]. Aliment Pharmacol Ther 1996;10:487–96.
   PubMedGoogle Scholar
• Thomas MC, Schlup MM. Budesonide substitution in Crohn’s disease relieves CNS toxicity of systemic steroids. Med J Aust 1998;169:560.
   PubMedGoogle Scholar
• Friend DR. Issues in oral administration of locally acting gluco- corticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 1998;12:591–60.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Therapy for ulcerative colitis. Curr Opin Gastroenterol 1998;14:312–6.
   Google Scholar
• D’Haens G, Rutgeerts P. Medical therapy for Crohn’s disease. Curr Opin Gastroenterol 1998;14:306–11.
   Google Scholar
• Hamedani R, Feldman RD, Feagan BG. Drug development in inflammatory bowel disease: budesonide—a model of targeted therapy. Aliment Pharmacol Ther 1997;11 Suppl 3:98–108.
   Google Scholar
• Brynskov J. Therapeutic options for patients with inflammatory bowel disease: New steroids. Drugs Today 1997;33:131–8.
   Google Scholar
• Löfberg R. New data on inflammatory bowel disease treatment with topical steroids. Res Clin Forums 1998;20:179–88.
   Google Scholar
• Danielsson Å, Löfberg R, Persson T, Salde L, Schoioler R, Suhr O, et al. A steroid enema, budesonide, lacking systemic effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol 1992;27:9–12.
   PubMedGoogle Scholar
• Edsbäcker S, Wollmer P, Nilsson Å, Nilsson M. Pharmacokinetics and gastrointestinal transit of budesonide controlled ileal release (CIR) capsules. Gastroenterology 1993;104:A695.
   Google Scholar
• Löfberg R, Danielsson Å, Salde L. Oral budesonide in active Crohn’s disease. Aliment Pharmacol Ther 1993;7:611–6.
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, et al. Oral budesonide for active Crohn’s disease. N Engl J Med 1994;331:836–41.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994;331:842–5.
   PubMed Web of Science ®Google Scholar